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Abstract
We investigated whether the high mobility group B 1 (HMGB1), an abundant nuclear protein in all mammalian cells, affects HIV-1
transcription. Intracellular expression of human HMGB1 repressed HIV-1 gene expression in epithelial cells. This inhibitory effect of
HMGB1 was caused by repression of long terminal repeat (LTR)-mediated transcription. Other viral promoters/enhancers, including simian
virus 40 or cytomegalovirus, were not inhibited by HMGB1. In addition, HMGB1 inhibition of HIV-1 subtype C expression was dependent
on the number of NFB sites in the LTR region. The inhibitory effect of HMGB1 on viral gene expression observed in HeLa cells was
confirmed by an upregulation of viral replication in the presence of antisense HMGB1 in monocytic cells. In contrast to what was found
in HeLa cells and monocytic cells, endogenous HMGB1 expression did not affect HIV-1 replication in unstimulated Jurkat cells. Thus,
intracellular HMGB1 affects HIV-1 LTR-directed transcription in a promoter- and cell-specific manner.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Transcription of the HIV-1 genome is regulated by the
interaction of viral long terminal repeat (LTR) cis-acting
sequences with a complex of viral regulatory proteins and
cellular transcription factors (Gaynor, 1992). The complex
interplay between the cellular and/or viral proteins and the
LTR leads to an up-/down regulation of transcription, which
in turn may play a role in the control of HIV-1 latency vs
active replication. The LTR can be divided into a modula-
tory region containing a negative regulatory element (NRE),
an enhancer/promoter region, and sequences coding for a
RNA stem-loop structure termed TAR. The interaction of
several constitutive and inducible transcription factors with
the enhancer/promoter element and the modulatory region
(reviewed in Pereira, 2000) leads to a basal level of tran-
scription with the majority of these transcripts terminating
prematurely. Transcription elongation is then controlled by
the interaction of TAR element with the viral trans-activator
protein Tat in conjunction with a cellular kinase (for a
review, see Karn, 1999). It has recently been suggested that
in addition to stimulating transcriptional initiation, NFB
can also stimulate elongation from the HIV-1 LTR in acti-
vated T cells (West et al., 2001).
Sequence polymorphisms in transcription factor binding
sites within the LTR have been linked to subtype specific
sequences in the gag and env genes (Johansson et al., 1995;
Gao et al., 1996; Montano et al., 1997; Naghavi et al.,
1999a; Jeeninga et al., 2000; Blackard et al., 2000). In
addition, several groups have correlated considerable intra-
subtype sequence variability (Estable et al., 1996, 1998) as
well as intersubtype polymorphisms (Montano et al., 1997,
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within the LTR to divergent transcriptional regulation of
HIV-1. We have reported that the promoter/enhancer activ-
ity of HIV-1 subtype C on average was higher than the
activities of the other subtypes (Naghavi et al., 1999b, 2001)
and that it correlated with the presence of the third potential
NFB site previously described (Johansson et al., 1995;
Salminen et al., 1996) as well as an alternative core-NRE
(Naghavi et al., 1999b, 2001).
The high mobility group (HMG) proteins were discov-
ered as abundant heterogeneous eukaryotic nonhistone com-
ponents of chromatin (Goodwin et al., 1973). They were
named for their rapid migration properties on polyacryl-
amide gels. Based on their sizes, sequence similarities, and
DNA-binding characteristics, HMG proteins can be divided
into three groups: HMGB, HMGA, and HMGN (Bustin,
2001), previously called HMG-1/2, HMG-I/Y, and HMG-
14/17, respectively (reviewed by Bianchi and Beltrame,
2000). HMGB proteins have a molecular mass of approxi-
mately 25 kDa and are characterized by the presence of
three different domains: the N-terminal A-domain, the cen-
tral B-domain (also referred to as HMG box A and B) each
of 80–90 highly basic amino acid residues, and the C-
terminal acidic tail (for a review see Bustin, 1999).
HMGB serves as a DNA-bending, -wrapping, and
-looping factor that can be required for transcription,
DNA repair, and recombination (Bianchi and Beltrame,
2000). Beyond this intracellular function, HMGB1 also
has an extracellular function in macrophages (for a re-
view see Muller et al., 2001) and plays an important role
in inflammation (Wang et al., 1999) and tumor metastasis
(Taguchi et al., 2000). Despite the accumulating data on
the extraordinary functions of HMGB1, very little is
known about the impact of HMGB1 on HIV-1 life cycle.
The HMGD which previously was suggested to be a
Drosophila homologue of vertebrate HMGB (Wagner et
al., 1992) has recently been shown to interact with dou-
ble-stranded RNA such as the TAR and Rev protein-
binding element (RBE) of HIV-1 (Arimondo et al.,
2000). Based on sequence homologies, the dorsal switch
protein (DSP1) in Drosophila (Lehming et al., 1994) has
been suggested to be the equivalent of vertebrate HMGB
(Canaple et al., 1997). Similar to DSP1 (Lehming et al.,
1994), the HMG box in HMGB1 can also interact with
the Rel domain of Dorsal (Brickman et al., 1999; Deco-
ville et al., 2000). Thus, it is conceivable that HMGB1
can also interact with the Rel protein NFB, which in
turn can regulate HIV-1 LTR directed transcription.
In this study, we investigated whether the intracellular
overexpression of HMGB1 had an effect on HIV-1 tran-
scription. We found that human HMGB1 repressed HIV-1
gene expression in monocytes and cultured epithelial cells
through inhibition of the LTR mediated transcription in a
promoter-, and cell-specific manner.
Results
HMGB1 represses HIV-1 gene expression in epithelial
cells
To test the effect of intracellular HMGB1 on HIV-1 gene
expression, the infectious proviral HIV-1 molecular clone
pNL4-3 (Adachi et al., 1986) was transiently transfected, in
the absence or presence of various concentration of the
pcDNA-HMGB1-sense (HMGB1-S), pcDNA-HMGB1-an-
tisense (HMGB1-A), or the empty pcDNA vector, into
HeLa cells. The extracellular p24gag and the human growth
factor (hGH) levels were then determined at various times
posttransfection in triplicate samples in at least two inde-
pendent experiments. In the presence of the HMGB1-S
plasmid, we observed a reduction of p24gag production from
the pNL4-3 at 24 h posttransfection (Fig. 1a and c). This
inhibitory effect of HMGB1 was dose dependent with a
maximum of fivefold reduction at 5 g of the HMGB1-S
plasmid and was seen when the levels were normalized to
internal control hGH. The repressive effect of HMGB1
decreased at 48 h posttransfection to about two- to three-
fold at 72 h posttransfection (Fig. 1b and d). No inhibition
of gene expression was observed from pNL4-3 in the pres-
ence of the empty pcDNA plasmid (Fig. 1a and b) or the
antisense HMGB1 plasmid (Fig. 1c and d), indicating that
the inhibitory effect observed was induced by the ectopic
production of the HMGB1.
HMGB1 represses HIV-1 LTR-mediated transcription
To investigate whether the HMGB1 repressive effect
was at the level of LTR-directed transcription, a CAT re-
porter gene construct containing HIV-1 LTR derived from
subtype B virus (pNLCATB) (Tan et al., 1995) was cotrans-
fected, in the presence or the absence of different amounts
of HMGB1-S or HMGB1-A, into HeLa cells. Fig. 2 repre-
sents the mean CAT values normalized to hGH numbers at
24 h posttransfection. Ectopic overexpression of HMGB1
inhibited transcription directed from the PNLCATB HIV-1
LTR (Fig. 2a). Again, the inhibitory effect of HMGB1 was
dose dependent with a maximum inhibition of 3.4-fold at
7 g of the HMGB1-S plasmid. Since the basal transcrip-
tion levels were low, we further looked for the effects of
HMGB1 in the presence of the viral protein Tat (Fig. 2b).
HeLa cells constitutively expressing Tat, HLtat (Schwartz
et al., 1990), were used for transfections in the Tat trans-
activation experiments. An earlier (visible already at 1 g of
the HMGB1-S plasmid) and more profound inhibitory ef-
fect of HMGB1, up to 9.2-fold at 3 g of the HMGB1-S
vector, was detected in the presence of Tat. However, an
obvious toxic effect was observed at higher concentrations
of cotransfected DNA (Fig. 2b at 5 g) in the presence of
Tat. These findings further corroborate that ectopic HMGB1
expression was responsible for the downregulation of viral
gene expression.
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HMGB1 does not repress transcription derived from other
viral promoters
In order to analyze the effect of HMGB1 on other viral
promoters, HeLa cells were transiently transfected with
cytomegalovirus (CMV) promoter reporter gene containing
constructs pCMVCAT (Zhao et al., 1996) and pCMVHGH
(Ramirez-Solis et al., 1990) or with the pSV--galactosi-
dase (Promega) control vector, which contains a simian
virus 40 (SV40) promoter/enhancer. As described above,
the transfections were done in the presence or the absence of
the internal control plasmid pCMVHGH, HMGB1-S,
Fig. 1. HMGB1 represses HIV-1 gene expression in HeLa cells. p24gag activity for pNL4-3, normalized to the hGH numbers produced from the internal
control plasmid (pCMVHGH), in the absence (indicated as no effector) or the presence of various amount of the HMGB1 sense (HMGB1-S) or the empty
pcDNA plasmid at 24 h (a) and 72 h (b) posttransfection. The standard deviations (SD) represent the median of three separate transfections. Cell supernatant
from untransfected HeLa cells were used as a negative control (not shown). Mean p24gag activity for the infectious clone normalized to the mean hGH
numbers, in the absence or presence of different concentration of HMGB1-S or the antisense HMGB1 plasmid (HMGB1-A) at 24 h (c) and 72 h (d)
posttransfection.
Fig. 2. HMGB1 represses HIV-1 LTR-mediated transcription in both HeLa and HLtat cells. Mean CAT values for the control plasmid pNLCATB, normalized
to hGH numbers, in the absence/HeLa (a) or presence/HLtat (b) of the viral protein Tat or/and different amount of HMGB1-S, HMGB1-A, or the empty
pcDNA plasmid at 24 h posttransfection. The CAT values in the absence of the HMGB1 plasmids are indicated as no effector. Cell extracts from untransfected
HeLa or HLtat were used as negative control (not shown). CAT and hGH untis refer to arbitrary units from the CAT and hGH ELISA, respectively. Error
bars indicate the SD values.
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HMGB1-A, or pcDNA. The mean CAT, and hGH values
detected at 24 h posttransfection are shown in Fig. 3. In the
presence of pCMVHGH, the CAT activity produced from
pCMVCAT were equal in the absence or the presence of the
various amounts (1–5 g) of the HMGB1-S or the antisense
HMGB1 plasmid (Fig. 3a), indicating that HMGB1 had no
effect on the CMV promoter. As is shown in Fig. 3b. no
gross differences were observed at the level of the hGH
Fig. 3. HMGB1 does not repress transcription derived from other viral promoters in HeLa cells. CAT values for pCMVCAT (a) or hGH numbers for
pCMVHGH (b), in the same transient transfection assay in the absence (indicated as no effector) or presence of different amounts of HMGB1-S or
HMGB1-A, at 24 h posttransfection. Error bars represent the median SD of three separate tansfections. Mean CAT values for pCMVCAT in the absence of
pCMVHGH (c) or mean hGH numbers for pCMVHGH in the absence of pCMVCAT (d) in the absence or presence of various amount of HMGB1-S,
HMGB1-A, or pcDNA at 24 h posttransfection. (e) Mean -galactosidase activity for pSV--galactosidase, a control vector that contains SV40 promoter/
enhancer, normalized to hGH values, in the absence or presence of different amounts of pCMVHMGB1-S, pCMVHMGB1-A, or pcDNA at 48 h
posttransfection.
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activity in the same experiment, which further confirmed
that HMGB1 had no effect on CMV promoter as seen in
Fig. 3a. Because the expression of both CAT and hGH are
under the control of the same CMV promoter, some of the
transfections were done only in the presence of pCMVHGH
or pCMVCAT to exclude a possible competition for tran-
scription factors. In the absence of the internal control
pCMVHGH, the level of CAT transcription directed by
CMV promoter was equal in the absence or the presence of
different concentration of the input HMGB1 plasmids (Fig.
3c). In the absence of pCMVCAT, the hGH activity was
similar in the absence or the presence of the various
HMGB1 plasmids at different concentrations (Fig. 3d). In
this experiment, a slight (1.5-fold) increase of hGH activity
was seen in the presence of HMGB1 sense cotransfection,
but this effect was not dose dependent.
The mean -galactosidase activity under the control of
an SV40 promoter/enhancer was normalized to hGH values
detected at 48 h posttransfection. The results are shown in
Fig. 3e. In comparison to the CMV promoter activity, a
more pronounced stimulatory effect (threefold) was ob-
served for the SV40 promoter/enhancer activity in the pres-
ence of 1–5 g of the HMGB1 sense plasmid. The -ga-
lactosidase production in the presence of different amounts
of the HMGB1 antisense vector or the empty control
pcDNA plasmid was similar to that of pSV--galactosidase
alone (indicated as no effector), indicating that the upregu-
latory effect detected here was induced by the ectopic pro-
duction of HMGB1. Thus, the inhibitory effect induced by
ectopic production of HMGB1 on HIV-1 LTR mediated
transcription was not observed in the context of other viral
promoters/enhancers such as those of CMV or SV 40. In
contrast, HMGB1 stimulated transcription from the SV 40
promoter/enhancer and to a lesser extent also the CMV
promoter.
HMGB1 represses HIV-1 subtype C expression in HeLa
cells, dependently of the number of NFB sites in the
LTR of these strains
HIV-1 subtype specific enhancer sequences such as
different number of NFB sites have been suggested to
play a role in divergent LTR-mediated transcription (Gao
et al., 1996; Montano et al., 1997, 1998, 2000; Verhoef et
al., 1999; Naghavi et al., 1999b, 2001; Blackard et al.,
2000; Jeeninga et al., 2000; Hunt et al., 2001). To analyze
whether the higher number of NFB sites (three sites
instead of two) present in the LTR of subtype C viruses
had any impact on the HMGB1 repression of HIV-1 gene
expression, a 12 bp mutation which replaced the extra
NFB site (NFBI, position 79 to 68) was introduced
into the LTR sequences from a previously described
(Naghavi et al., 1999b) subtype C strain (GM6439:1C).
The relevant part (174 to 46) of the LTR alignment of
the consensus subtype B and the wt-, (GM6439C-wt) or
mutant (GM6439C-mB, containing only two functional
NFB sites) subtype C is presented in Fig. 4. These LTR
clones were then tranferred into infectious clone pNL4-3
and tested in single round replication assay in the absence
or the presence of HMGB1 in HeLa cells. The mean
p24gag activity normalized to the mean hGH numbers for
the wt subtype B (pNL4-3) and the wt or mutant subtype
C (pNL6439C-wt and pNL6439C-mB, respectively) vi-
ruses, in the presence of 5 g of the HMGB1-S or
HMGB1-A at 24 and 48 h posttransfection are shown in
Fig. 5. In the presence of the antisense HMGB1, the viral
activity of wt or mutant subtype C virus was 1.4-fold
higher than that of the control subtype B (pNL4-3) virus
as well as the same control virus in the absence of an
effector plasmid (indicated as no effector) at 24 h (Fig.
5a) posttransfection. Again, ectopic expression of
HMGB1 repressed the viral activity of the pNL4-3 by
3.4- and 4.1-fold at 24 h (Fig. 5a) and at 48 h posttrans-
fection (Fig. 5b), respectively. The same pattern of viral
activity at the various times posttransfection was found
for the mutant subtype C virus in the presence of
HMGB1-S but not for the wt virus from the same strain.
The p24gag activity of the pNL6439C-wt virus was more
or less similar in the presence of the HMGB1 sense and
the antisense plasmids, indicating no inhibitory effect of
HMGB1. Thus, it seems that the extra NFB site might
overcome the inhibitory effect of HMGB1 on HIV-1
subtype C replication.
Fig. 4. Nucleotide sequence alignment of HIV-1 LTR, including the relevant part core-NRE, enhancer/promoter region, and the TAR element (174 To46)
of the complete alignment (382 to 113). The most important transcription factor binding sites involved in viral gene expression are indicated (i.e.,
core-NRE, ETS/RBF-1, LEF, RBF-2, NFB, SP1, TATA, and TAR). The letters before the sample code (GM) denote the country of origin of the virus strain
(Gambia). The letter after the sample code indicates the HIV-1 subtype (subtype B and C) based on the LTR region. wt or NFBI-mutant (mB) subtype
C LTRs are marked. Deviations from the subtype B consensus LTR sequences are indicated.
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HMGB1 does not repress HIV-1 replication in
unstimulated Jurkat cells
In order to assess whether the repression of HIV-1
expression observed by intracellular HMGB1 in HeLa
cells could also be seen in T cells, Jurkat cells were
cotransfected with pNL4-3 in the presence or the absence
of HMGB1-S or HMGB1-A vector. Mean p24gag concen-
tration for the infectious clone at various times posttrans-
fection (day 1 to day 3), in the presence or the absence of
5 g HMGB1 vectors are shown in Fig. 6a. The level of
viral replication in the presence of HMGB1-S and
HMGB1-A was unchanged to that of the infectious clone
alone at different time points, indicating that HMGB1 did
not inhibit viral replication in unstimulated Jurkat cells.
This finding may suggest an inhibitory effect of HMGB1
through NFB because there is no activated NFB in the
nucleus of unstimulated Jurkat cells in contrast to HeLa
cells.
Antisense HMGB1 upregulates HIV-1 replication in
monocytic cells
Because as in HeLa cells, activated NFB is also found
in the nuclei of monocytes, we tested the role of HMGB1 on
HIV-1 replication in the THP-1 monocytic cell line. THP-1
cells were cotransfected with pNL4-3 in the presence or
absence of HMGB1-S or HMGB1-A. Fig. 6b represents the
mean p24gag concentration at day 1 to day 3 posttransfec-
tion. In the presence of 5 g of the HMGB1-S vector, the
level of p24 activity was reduced at day 2 but was more or
less similar to that of the pNL4-3 alone at day 3 (Fig. 6b).
Notably, a 4.3-fold upregulation of viral replication was
observed in the presence of 5 g of the antisense HMGB1
plasmid at 24 h posttransfection. This upregulatory effect of
HMGB1-A on the viral replication was decreased at 48 h
posttransfection to 1.4–3.4-fold. HMGB1 mRNA is consti-
tutively expressed in monocytes/macrophages (Wang et al.,
1999). Thus, HMGB1-S cotransfection might not add addi-
Fig. 5. HMGB1 represses HIV-1 subtype C expression in HeLa cells, dependently of the number of NFB sites in the LTR of these strains. Mean p24gag
activity normalized to the mean hGH numbers for the control wt subtype B (pNL4-3) and the wt or mutant subtype C (pNL6439C-wt and pNL6439C-mB,
respectively) viruses, in the presence of 5 g of the HMGB1-S or HMGB1-A at 24 h (a) and 48 h (b) posttransfection. p24gag activity for the reference plasmid
pNL4-3 in the absence of HMGB1 vectors is indicated as no effector. The standard deviations represent the median of three separate transfections.
Fig. 6. HMGB1 effects on HIV-1 replication in Jurkat and THP-1 cells. (a) Mean p24gag activity for pNL4-3 in the absence (indicated as no effector) or
presence of 5 g of the HMGB1 sense (HMGB1-S) or the antisense HMGB1 (HMGB1-A) at day 1 to day 3 (shown as d-1, d-2, and d-3, respectively)
posttransfection in cotransfected Jurkat cells. (b) p24gag activity for the infectious clone in the absence or presence of 5 g of HMGB1-S or HMGB1-A at
different days posttransfection (d-1 to d-3) in cotransfected THP-1 cells. The standard deviations are indicated as error bars. Supernatants from untransfected
Jurkat or THP-1 cells were used as negative control (not shown).
184 M.H. Naghavi et al. / Virology 314 (2003) 179–189
tional biological anti-HIV-1 activity in this cell type to the
same extent as was observed in HeLa cells.
Discussion
Here we found that ectopic overexpression of HMGB1
repressed HIV-1 gene expression in an epithelial cell line.
We further investigated whether this inhibitory effect of
HMGB1 was a result of repression of the HIV-1 LTR-
mediated transcription. We indicated that HMGB1 had a
repressive effect on basal-, as well as Tat induced-transcrip-
tion directed by the 5-LTR in HeLa cells. This inhibitory
effect of HMGB1 was LTR specific in the sense that
HMGB1 in contrast stimulated the transcription from the
SV 40 promoter/enhancer. In accordance with these find-
ings, HMGB1 has been shown to stimulate transcription
from other viral promoters such as the adenovirus major late
promoter (MLTF) and the SV40 late promoter (Tremethick
and Molloy, 1989).
HMGB1 protein may downregulate HIV-1 LTR-medi-
ated transcription by interacting with other cellular, and/or
viral factors that directly or indirectly are involved in the
viral transcription. HMGB1 has been shown to interact with
several transcription regulatory proteins such as steroid hor-
mone receptors, p53, Hox proteins, octamer transcription
factors, the TATA binding protein (hTBP), and MLTF (for
a review, see Bianchi and Beltrame, 2000). In addition,
HMGB1 regulates the activity of several transcription fac-
tors, including the glucocorticoid receptor (GR) (Calogero
et al., 1999) as well as the receptor for the advanced gly-
cation end products (RAGE) (Huttunen et al., 2000) through
interaction with NFB. A general observation is that
HMGB1 facilitates the assembly of site-specific DNA bind-
ing proteins to their cognate binding sites within the chro-
matin. The region of HMG box domain involved in the
interaction with other proteins is still not known. It has
recently been proposed that HMGB1 can interact with many
apparently unrelated proteins by recognizing short amino
acid sequences (Dintilhac and Bernues, 2002). In the con-
text of HIV-1 gene expression, another HMG protein, from
the HMGA family (previously called HMGI), has been
shown to modulate interaction of transcription factors to the
U5 region of the 5LTR of the virus (Henderson et al.,
2000).
Based on sequence homologies, DSP1 in Drosophila,
which can convert members of the Rel family of transcrip-
tion factors, NFB and the Drosophila protein Dorsal, from
transcriptional activators to repressors (Lehming et al.,
1994), has been suggested to be the equivalent of vertebrate
HMGB1 (Canaple et al., 1997). Similar to DSP1, the HMG
box in HMGB1 can also interact with the Rel domain of
Dorsal (Brickman et al., 1999; Decoville et al., 2000). Thus,
we investigated a possible functional interaction between
HMGB1 and NFB in the context of HIV-1 LTR. By
deletion of the extra NFB site (NFBI) present in the LTR
of subtype C viruses (Naghavi et al., 1999b, 2001), we
could show a higher inhibitory activity of HMGB1 on the
NFBI mutant subtype C LTR compared to the wt subtype
C LTR. It should be noted that the interaction of HMGB1
with NFB alone cannot be the only explanation for
HMGB1 repression of HIV-1 gene expression because sev-
eral numbers of NFB sites are also present in the SV40
promoter/enhancer which, in contrast to the LTR, is stimu-
lated by HMGB1. Thus, it can be speculated that a ternary
complex forms between HMGB1, NFB, and another yet
unidentified repressor(s) which directly or indirectly interact
with a specific element in the LTR. In keeping with this
idea, we have previously correlated a third potential NFB
site and/or an alternative USF binding site (E-box) within
the NRE in the LTR of HIV-1 subtype C to a higher
promoter/enhancer activity (Naghavi et al., 1999b). It has
also been shown that a nuclear matrix-specific factor inhib-
its NFB activity through interaction with a specific seg-
ment within the NRE in HIV-1 infected T cells and mono-
cytes (Hoover et al., 1996). Also, a CCAAT/enhancer
binding protein (C/EBP) in brain-derived cells can bind to
the USF binding site within the NRE (E-box) and negatively
regulate the HIV-1 promoter by interacting with NFB sites
(Mondal et al., 1994). In addition, the NRE region within
the IFN- promoter has been identified as a position inde-
pendent silencer of the NFB sites (Nourbakhsh et al.,
1993). Furthermore, sequence similarity between core
NREs of HIV-1, IFN-, and IL-2R has been reported
(Smith and Greene, 1989; Nourbakhsh et al., 1993). Also in
agreement with our speculation, the presence of a NRE
adjacent to the Rel binding sites, as in the case of HIV-1
LTR and IL-2R gene (Smith and Greene, 1989), has been
correlated to the “switching” function of DSP1 in the Dro-
sophila Zen gene and interferon- (IFN-) gene (Lehming
et al., 1994). However, a later report by the same group
showed the inability of the NRE to mediate repression by
Rel proteins (Brickman et al., 1999). Whether the NRE in
the HIV-1 LTR plays any role in the assembly of a NFB
repressing complex remains to be elucidated.
We further investigated whether the inhibitory effect of
HMGB1 on HIV-1 gene expression observed in epithelial
cells could also be seen in the context of viral replication in
T cells or monocytes. The level of viral replication was
unchanged in the presence or the absence of the HMGB1-S
vector in a transiently cotransfected monocytic cell line,
THP-1, or in Jurkat cells. Western blot analysis on cell
lysates from HeLa, Jurkat, and THP-1 using polyclonal
antibodies against HMGB1 showed a higher level of endog-
enous HMGB1 in the latter cell lines compared to that of in
HeLa cells (data not shown). Thus, HMGB1-S cotransfec-
tion might not add additional biological anti-HIV-1 activity
in these cell types to the same extent as was observed in
HeLa cells. Notably, a possible negative regulatory role of
intracellular HMGB1 on HIV-1 replication was corrobo-
rated by results showing an upregulation of viral gene ex-
pression in the presence of an antisense HMGB1 construct
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in THP-1 cells. This effect of HMGB1 antisense was not
observed in unstimulated Jurkat cells. However, in contrast
to T cells, monocytes upon stimulation constitutively pro-
duce and secrete high amounts of HMGB1 (Wang et al.,
1999) which could be blocked by the antisense HMGB1
mRNA in the cytoplasm of the cells. This could in turn lead
to the upregulation of HIV-1 replication as observed. The
monocytes in our cotransfection were most probably acti-
vated from the manipulations during the experiment. It was
recently reported that extracellular HMGB1 stimulates
proinflammatory cytokine synthesis such as TNF, IL-1, and
macrophage inflammatory protein (MIP)-1 and MIP-1 in
human monocytes (Andersson et al., 2000). Secretion of the
beta-chemokines has been correlated to the downregulation
of newly HIV-1 infected human monocyte-derived macro-
phages (Barker et al., 1998). The inhibitory effect of
HMGB1 on viral gene expression observed in the present
study could already be detected in a single round replication
assay, i.e., within 24 h posttransfection of HeLa cells. Thus,
the block of HIV-1 replication through the extracellular
HMGB1 induced beta-chemokine induction is unlikely in
our experimental set up because that would require more
than one round of HIV-1 replication. On the other hand, as
we suggested earlier, this finding may provide additional
evidence that the HMGB1 inhibitory effect is mediated
through NFB because there is no activated NFB in the
nucleus of unstimulated Jurkat cells in contrast to HeLa
cells or monocytes. This is supported by our preliminary
finding showing a 4.5-fold upregulation of viral replication
in the presence of 3 g of the antisense HMGB1 plasmid in
cotransfected Jurkat cells after PMA stimulation (data not
shown). However, our findings in Jurkat cells and mono-
cytes seem to be insufficient for suggesting that HMGB1
plays a role in HIV-1 replication. To investigate this further,
it would be interesting to determine HMGB1 activity in
PBMCs and/or macrophages.
Data about HIV-1 biological activity, transmission, and
pathogenicity is predominantly based on subtype B virus
analysis, while subtypes C and E are the most prevalent
subtypes in the world (UNAIDS/WHO, 2000). We (Johan-
sson et al., 1995; Naghavi et al., 1999b, 2001) and others
(Gao et al., 1996; Montano et al., 1997, 1998, 2000; Ver-
hoef et al., 1999; Jeeninga et al., 2000; Blackard et al., 2000;
Hunt et al., 2001) have indicated subtypes C and E specific
LTR sequences such as different number of NFB sites,
which we suggest here, to be of importance for HMGB1
inhibition of viral transcription. These viruses may have
gained such subtype specific sequences to overcome the
inhibitory effect of HMGB1 in monocytes. This may further
explain the faster expansion and the global dominance of
these viruses. As an explanation, we suggest that HMGB1
interaction with NFB may bring about a repression state of
the chromatin at the LTR by recruiting other proteins nec-
essary for repression. In keeping with this idea, the exis-
tence of a DSP1-associated putative transcriptional repress-
ing complex, which can be recruited to DNA by interaction
with various members of the Rel family of transcriptional
activators, has been suggested (Lehming et al., 1998). Con-
stitutive HMGB1 mRNA expression in macrophages may
therefore be involved in the control of HIV-1 replication,
possibly functioning as a DSP1 homologue in these cells.
Materials and methods
PCR amplification and subcloning of human HMGB1
Recombinant human HMGB1, 651 base pair, was am-
plified from a human brain Quick-Clone cDNA (Clontech,
Polo Alto, CA) using the following primers; forward prim-
er: 5-GATGGGCAAAGGAGATCCTAAG-3 and reverse
primer: 5-GCGGCCGCTTATTCATCATCATCATCTTC-
3. The PCR product was ligated into pCR2.1-TOPO vector
(Invitrogen, San Diego, CA).
Plasmid constructs
The HMGB1 amplicon in the pCR2.1 vector was di-
gested with EcoRI, dephosphorylated, and ligated into a
mammalian expression vector, pcDNA3.1 () (Invitrogen).
The pcDNA-HMGB1-sense (HMGB1-S) and pcDNA-
HMGB1-antisense (HMGB1-A) constructs were identified
directly by BamHI digestion and the positive clones were
confirmed by sequencing. The full-length HIV-1 infectious
clone containing LTR from a HIV-1 subtype C strain
(GM6439:1C) has been described before (Naghavi et al.,
2001, 1999a,b) (Genbank accession number AF102202).
pNL4-3 (Adachi et al., 1986), pNLCATB (Tan et al., 1995),
pNLCATXSXB (Naghavi et al., 1999b), pCMVHGH
(Ramirez-Solis et al., 1990), and pCMVCAT (Zhao et al.,
1996) have been described previously. The pSV--galacto-
sidase (Promega, Modison, WI) control vector contains the
SV40 promoter and enhancer, which drive transcription of
the lacZ gene and further the expression of the -galacto-
sidase enzyme.
Mutant LTR
To generate HIV-1 subtype C LTR containing mutations in
the potential third NFB site, the pCR2.1 vector containing
LTR from subtype C (TA-6439:2) was used as template
(Naghavi et al., 1999b). The PCR was performed in two
separate reactions containing oligonucleotides (1 M each)
LTR1-SX and NFBI-EX-A (mix I) or LTR3-SB and NFBI-
EX-S (mix II). LTR1-SX contains StuI and XhoI cloning sites
and LTR3-SB contains SaII and BamHI sites as previously
described (Naghavi et al., 1999b). NFBI-EX-A and NFBI-
EX-S primers are complementary and each contains a 12 bp
substitution, which replace the extra NFB site (NFBI, posi-
tion79 to68) (see Fig. 4) with EcoRV and XbaI sites. The
sequences of these primers were as follows: NFBI-EX-A
(5-TCCACACCTCCTTCTAGAGATATC TGGAAAGTC-
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CCAGCGGAAAGTCCCTTCTGTGTC-3) and NFBI-
EX-S (5-GACACAGAAGGGACTTTCCGCTGGGACTT-
TCCAGATATCTCTAGAAGG AGGTGTGGA-3). The
restriction enzyme sites are underlined. Equal amounts of the
two PCR fragments were mixed and used as template in a
nested PCR reaction primed by addition of oligonucleotides
LTR1-SX and LTR3-SB as previously described (Naghavi et
al., 1999b). The XhoI-BamHI PCR fragment was then trans-
ferred into pNLCATXSXB (Naghavi et al., 1999b). The se-
quences of the NFBI mutant (6439C-mB) were confirmed
by sequencing. To generate full-length HIV-1 clone containing
subtype C LTR mutated in the extra NFB site (pNL6439C-
mB), the resulting mutant LTR sequence was inserted as
AatII-BssHII fragment into pNL4-3 as previously described
(Naghavi et al., 1999b).
Cells and transfections
For transfections, 0.5  106 HeLa cells were seeded in
each 60 mm dish 1 day before transfections. Transfection of
HeLa cells was performed using FuGENE 6 transfection
reagent (Boehringer Mannheim), adding 2 l reagent per g
DNA. Transfection efficiency was normalized to human
growth hormone (hGH) expressed from the cotransfected
pCMVHGH internal control plasmid, which was present in
all transfections, as described previously (Naghavi et al.,
1999b). One microgram of each pNL4-3-derived plasmid
(wt subtype B and wt or NFBI-mutated subtype C) was
mixed with 1 g of pCMVHGH in the presence or absence
of 1–5 g of HMGB1-S or HMGB1-A or the empty plas-
mid (pcDNA). The total amount of DNA in each transfec-
tion was adjusted to 7 g by the addition of pBluescript
DNA. The FuGENE 6 transfection reagent was added into
the DNA mix according to the standard protocol (Boehr-
inger Mannheim). Cell culture supernatants were collected
at various times posttransfection (0, 24, 48, and 72 h) and
hGH and HIV-1 p24gag production were measured as de-
scribed below. To look for the effect of HMGB1 on expres-
sion of the subtype C viruses containing wt or NFBI-
mutated LTR, the respective pNL4-3-derived plasmid
(pNL6439-wt and pNL6439C-mB, respectively) was in-
cluded in the absence or presence of 5 g of the HMGB1-S
or HMGB1-A in the cotransfection of HeLa cells as de-
scribed above.
In order to analyze the effect of HMGB1 on the
context of the LTR promoter, pNLCATB was included in
the transfection of HeLa cells. Transfection was per-
formed with the DNA– calcium phosphate coprecipitation
technique as described previously (Naghavi et al.,
1999b). Three micrograms of each pNLCATB was mixed
with 3 g of pCMVHGH in the presence or absence of
3–7 g of HMGB1-S or HMGB1-A or the empty plasmid
(pcDNA). The total amount of DNA was filled up to 15
g by the addition of pBluescript DNA. To look for the
HMGB1 effects on Tat trans-activated transcription, the
HeLa-derived cell line HLtat which constitutively ex-
presses a truncated 14 kDa functional form of Tat
(Schwartz et al., 1990), was used for transfections. Cells
(4.5  105) were seeded 1 day before transfections. The
cells were cotransfected with 1 g of pNLCATB and 1
g of pCMVHGH in the presence or absence of 1–5 g
of HMGB1-S or the empty plasmid. Transfection was
carried out using FuGENE 6 (Boehringer Mannheim)
according to the protocol described above. At 24 h post-
transfection, cell lysates were obtained and analyzed as
described before (Naghavi et al., 1999b).
To investigate the effect of HMGB1 on the context of
other viral promoters, HeLa cells were cotransfected with
1 g of pSV--galactosidase (Promega) control vector or
1 g of pCMVCAT or 1 g of pCMVHGH (Ramirez-
Solis et al., 1990) in the presence or absence of pCM-
VHGH (1 g), HMGB1-S (1–5 g), HMGB1-A (1–5
g), or pcDNA (1–5 g). FuGENE 6 transfection reagent
was used for transfection as described above. In the CAT
and the hGH assay, the cells were harvested 24 h post-
transfection and analyzed (see below). In the -galacto-
sidase assay, the cell culture supernatants were collected
at 48 h posttransfection and tested in hGH ELISA. The
cells were then harvested and analyzed for -galactosi-
dase activity as described below.
The human T cell lymphoma line Jurkat (ATCC) or the
human acute monocytic leukemic cell line THP-1 (ATCC)
was seeded at 0.7  106 cells or 1.5  106 cells per well in
a 24-well dish, respectively. The next day, the cells were
transfected using FuGENE 6 transfection reagent, as de-
scribed for HeLa cells. Cell culture supernatants from rep-
lication assay were analyzed at different times posttransfec-
tion (day 1 to day 3) as described below.
p24gag, CAT, hGH, and -galactosidase ELISA
To determine the p24gag levels produced in transfections
with pNL4-3 derived plasmids, cell culture supernatants
were analyzed directly in a p24gag antigen capture
HIVAG-1 ELISA (Abbott) according to the manufacturer’s
instructions. Cell culture supernatants adjusted to 1% Triton
X-100 and appropriately diluted were analyzed in hGH
ELISA to determine the transfection efficiency. The p24
concentrations (pg/ml) were normalized to hGH numbers.
Cell extracts from the transfections in the absence (in HeLa)
or presence of Tat (in HLtat) were diluted 10 and 1000
times, respectively, and further analyzed in CAT ELISA
and hGH ELISA (Boehringer Mannheim) according to the
manufacturer’s instructions. The cell culture supernatant at
48 h posttransfection were diluted 10000 times and ana-
lyzed in hGH ELISA. The -Galactosidase Enzyme Assay
System (Promega) was performed on the cell lysates from
the transfections following the standard protocol. The CAT
and -galactosidase numbers were normalized to hGH val-
ues. Each LTR, CMV, or SV40 promoter was tested in
triplicates in at least two independent experiments.
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